Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in adults with neuromyelitis optica spectrum disorder
NL-OMON49042Phase 3Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Time to first adjudicated On-Trial Relapse. Planned start Feb 2020; status: withdrawn.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NL-OMON49042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49042.